Related Experiment Video

Updated: Jun 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Mark Wade1, Geoffrey M Wahl

  • 1Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.

Molecular Cancer Research : MCR
|January 17, 2009
PubMed

Insights

Personalized cancer therapy relies on understanding tumor genetics. This review explores p53 pathway dysregulation by Mdm2 and Mdmx, highlighting Mdmx as a target for new cancer therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genomic and proteomic profiling of tumors is crucial for personalized cancer therapy.
  • The p53 tumor suppressor pathway is frequently inactivated in human cancers.
  • Inactivation can occur despite wild-type p53, through mechanisms like Mdm2 and Mdmx regulation.

Purpose of the Study:

  • To review current models of p53 regulation by Mdm2 and Mdmx.
  • To present the rationale for developing Mdmx-specific therapeutics.
  • To identify new therapeutic targets in oncology.

Main Methods:

  • Literature review of p53 pathway regulation.
  • Analysis of Mdm2 and Mdmx roles in cancer.
  • Examination of Mdmx structure and function.

Main Results:

  • p53 pathway inactivation is a hallmark of cancer.
  • Mdm2 and Mdmx are key regulators of p53.
  • Mdmx presents a promising target for novel therapeutics.

Conclusions:

  • Understanding p53 regulation by Mdm2 and Mdmx is vital for cancer treatment.
  • Targeting Mdmx offers a potential strategy for developing new anti-cancer drugs.
  • Further research into Mdmx structure and function can guide therapeutic design.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...